Stock Ticker

  • Loading stock data...

NTRB: Tiny Float Emerging Pharma Play Pulls Back to Trendline Support

We love a good pharma story that can cook on a small float. That’s why we are putting NTRB Nutriband Inc. (OTCMKTS: NTRB) in front of you right now.

The company is moving and shaking in the space with a corner on the transdermal patch theme, and just made a play to gobble up Carmel Biosciences, a pharmaceutical company that addresses critical needs in the cardiovascular and metabolic therapies space and just got great news from the FDA.

NTRB trades on a tiny float (under 2.5M shares) and finally pulled back to test trendline support and give us a chance to possibly climb on the elevator before it potentially heads up to the next floor. Just a simple flash back up to test recent highs could represent as much as 80% on the upside.

So it’s worth having a closer look.

Symbol:  NTRB

Company:  Nutriband Inc.

Quote:  http://finance.yahoo.com/q?s=NTRB

Latest News:  http://finance.yahoo.com/q/h?s=NTRB+Headlines

Key Points:

 

  • NTRB trades on a very tight float of just 2.3 million shares, so any influx of new interest could potentially send this stock into orbit.
  • NTRB is logging RSI prints under 40 right now, pointing to a massively oversold stock now looking to potentially spring back the other way.
  • NTRB is currently testing key trendline support as liquidity rises in this newly discovered pharma play.
  • NTRB just signed on to swallow Carmel Biosciences, new FDA approval in tow.
  • NTRB also just signed an exclusive 20-year, $90 million distribution deal with a Korean distributor to penetrate Asian markets.

 

 

Nutriband Inc. (OTCMKTS: NTRB) is a very speculative play that has the potential to be powered by its announcement out last month that it has signed a Letter of Intent to acquire 100% of Carmel Biosciences, a pharmaceutical company that addresses critical needs in new drug and liquid reformulation for cardiovascular and metabolic therapies.  

 

Why could this be such a big deal? Because Carmel Biosciences received FDA approval a few months ago for PREXXARTAN, the first and only approved oral liquid dosage form of the angiotensin receptor blocker (ARB) valsartan in the United States.

 

Nutriband plans to complete the deal, valued at approximately $3.8 million, through payment of 450,000 restricted common shares of the Company’s stock. Remember: this stock is just toting around a little over 2 million shares on the float. That means that any sort of extra attention has the potential to push the stock like a feather caught in an updraft.

 

NTRB is a Pharmaceutical and Health company with a specific focus on Transdermal and Topical technologies.

 

Nutriband is a pharma play based in Orlando. According to company materials, “Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.”

 

The company operates primarily in the health supplement market. Its product line consists of an energy patch line, a weight management patch line, a multivitamin patch line, a children’s multivitamin patch line, an amino acid patch line, an anti-wrinkle patch line, an insect repellant patch line, a detox patch line, a PMS patch line, a sleep patch line, and a nausea and motion sickness patch line.

 

According to the deal release, “PREXXARTAN (valsartan oral solution) is indicated for treatment of hypertension in adults and children six years and older. PREXXARTAN is also indicated for use as therapy for the treatment of heart failure (NYHA class II-IV). Additionally, PREXXARTAN has also been indicated for stable left ventricular failure or left ventricular dysfunction after myocardial infarction.”

 

“The Carmel Biosciences team combines a deep understanding of lipid biochemistry and clinical expertise in the cardiovascular and metabolic space,” stated Gareth Sheridan, CEO of Nutriband. “Carmel’s focus in the reformulation of drugs with a high degree of safety and efficacy allows improved access to patients who have difficulty swallowing tablets or capsules and provides enhanced usage of these widely acclaimed products.”

 

Just before that, the company announced that it had signed an exclusive 20-year, $90 million distribution agreement for its transdermal consumer product lines with Best Choice Inc., a Korean consumer products distributor with a 20-year history of working with major chain retailers, including Costco and Lotte Department Stores.  

 

As for the technical side, the stock has been charging up the charts in a nice steady trend basically all year. If you’ve been looking for a pullback to get involved, right now is the time, which is why we are bringing this one to your attention.

 

We are testing trendline support right now. And with just a tiny 2.3 million shares rattling around on the float, if this news spreads and the stock gets some traction, a major squeeze is not out of the question here.

About NTRB

NTRB (Nutriband Inc.) is a Pharmaceutical and Health company with a specific focus on Transdermal and Topical technologies.

Nutriband is a pharma play based in Orlando. According to company materials, “Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.”

The company operates primarily in the health supplement market. Its product line consists of an energy patch line, a weight management patch line, a multivitamin patch line, a children’s multivitamin patch line, an amino acid patch line, an anti-wrinkle patch line, an insect repellant patch line, a detox patch line, a PMS patch line, a sleep patch line, and a nausea and motion sickness patch line.

Nutriband Inc. was incorporated in 2016 and is headquartered in Oviedo, Florida.

 

Published by Van Bettauer

Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https://plus.google.com/100770875710593766367/posts

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts